Skip to content
AnalystLens

Medpace Holdings 8-K Report, Material Agreement (Mar 31, 2025)

Reports
Material Agreements·Exhibits & Filings
Filing Date
Filed March 31, 2025
Period End
March 28, 2025
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K filed March 31, 2025. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (MEDP) disclosed in this Form 8-K filed March 31, 2025 that, on March 28, 2025, its wholly owned subsidiaries Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No. 7 to Loan Documents with PNC Bank, National Association, relating to the company's unsecured credit facility.

The principal change in Amendment No. 7 is an extension of the expiration date of the revolving credit note to March 31, 2026. The filing describes the amendment as a material definitive agreement under Item 1.01 and attaches it as Exhibit 10.1, incorporated by reference. The filing does not include any other financial results, guidance, or operational disclosures.

For investors, the filing is primarily a routine maintenance event for the company's revolving credit arrangement, keeping the unsecured facility available through March 31, 2026. The full terms of the amendment are set out in Exhibit 10.1, which the summary above does not reproduce.

Key Highlights

  1. Entry into Amendment No. 7 to Loan Documents on March 28, 2025, with PNC Bank, National Association, relating to the company's unsecured credit facility.
  2. Amendment No. 7 extends the expiration date of the revolving credit note to March 31, 2026.
  3. Borrower is Medpace, Inc. and guarantor is Medpace IntermediateCo, Inc., both wholly owned subsidiaries of Medpace Holdings, Inc.
  4. The filing is made under Item 1.01 (Entry into a Material Definitive Agreement) and Item 9.01 (Financial Statements and Exhibits).
  5. The full amendment is filed as Exhibit 10.1 and incorporated by reference; the filing states that the description is qualified in its entirety by the exhibit.
  6. The filing contains no financial statements, results, or guidance; its disclosure is limited to the credit facility amendment and exhibits.

Frequently Asked Questions

  1. What did Medpace Holdings agree to in this filing?

    On March 28, 2025, subsidiaries Medpace, Inc. (borrower) and Medpace IntermediateCo, Inc. (guarantor) entered into Amendment No. 7 to Loan Documents with PNC Bank, National Association, in connection with the company's unsecured credit facility.

  2. What is the key change under Amendment No. 7?

    Amendment No. 7 extends the expiration date of the revolving credit note to March 31, 2026.

  3. Who are the parties to the amendment?

    The parties are PNC Bank, National Association, and the Medpace subsidiaries Medpace, Inc. (as borrower) and Medpace IntermediateCo, Inc. (as guarantor). The filing identifies Medpace Holdings, Inc. as the parent company.

  4. Where can investors find the full terms of the amendment?

    The full amendment is filed as Exhibit 10.1 to this Form 8-K, dated March 28, 2025, and is incorporated by reference into the filing. The description in the 8-K is qualified in its entirety by the exhibit.